Life Scientist > Biotechnology

Progen anti-cancer compound earns orphan drug status

04 May, 2004 by Iain Scott

Brisbane-based Progen (ASX:PGL) has earned 'orphan drug' status from the US Food and Drug Administration for its much-touted PI-88 compound, for treatment of malignant melanoma.


Genetic Solutions finds partner for US, Canadian market

03 May, 2004 by Graeme O'Neill

Brisbane biotech Genetic Solutions is set to create a tidal wave in the international beef industry's gene pool, after licensing its GeneStar DNA markers to new US partner Bovigen Solutions.


Meditech chairman, CEO resign at AGM

30 April, 2004 by Melissa Trudinger

Biotech veteran Bob Moses, the chairman of Melbourne biotech company Meditech (ASX:MTR), had harsh words yesterday for the shareholders whose lack of support for the re-election of CEO Chris Carter as a director on the board led to both he and Carter resigning their positions.


Imugene soars on vaccine trial result

30 April, 2004 by Graeme O'Neill

Shares in Sydney animal-health biopharma Imugene Limited (ASX:IMU) soared yesterday on news that animal trials have confirmed the efficacy of the company's new vaccine for controlling one of the international pig industry's most costly diseases.


Medica to take over subsidiary Cytopia

29 April, 2004 by Graeme O'Neill

Brisbane-based pooled development fund Medica Holdings (ASX:MCA) is committing body and spirit to the drug-discovery race by taking a 100 per cent shareholding in its Melbourne subsidiary Cytopia -- and adopting Cytopia's name.


BIO 2004: Better believe it -- credibility rules

29 April, 2004 by Melissa Trudinger

Building your credibility and getting past the introductory meeting are the two goals biotech companies going to BIO should keep in mind, according to US-based biotech communications specialist Doug MacDougall.


Big pharma, CRCs can work together: AstraZeneca czar

29 April, 2004 by Melissa Trudinger

The thing AstraZeneca finds hardest about its relationship with the Cooperative Research Centre for Chronic Inflammatory Diseases is coping with incompatible timezones.


Austin spin-off XenoTrans earns Geron backing

28 April, 2004 by Melissa Trudinger

US biotechnology company Geron has taken a 25 per cent equity position in Austin Research Institute spin-off XenoTrans, in return for granting the company a non-exclusive licence to use Geron's nuclear transfer technology to produce transgenic pigs for xenotransplantation, and a share in future revenues.


Virax begins prostate cancer vaccine trial

28 April, 2004 by Graeme O'Neill

Melbourne immunotherapy developer Virax Holdings (ASX:VHL) has begun a pre-clinical trial of its novel candidate vaccine for late-stage prostate cancer at the Royal Adelaide Hospital Cancer Centre.


GroPep posts fourth consecutive positive quarter

28 April, 2004 by Graeme O'Neill

Adelaide biopharma GroPep (ASX:GRO) today announced its fourth consecutive quarter of positive operating and net cash flow.


CSIRO, Bayer in RNAi deal

27 April, 2004 by Graeme O'Neill

International agbiotech company Bayer CropScience has acquired a licence from CSIRO to develop new crops using the patented RNA interference (RNAi) gene-silencing technology developed by CSIRO Plant Industry researchers.


AGT pipeline boosted in merger with US firm

27 April, 2004 by Melissa Trudinger

AGT Biosciences (ASX:AGT) has merged with US company ChemGenex Therapeutics to create a genomics-driven pharmaceutical company with two products in Phase II clinical trials.


Obesity drug alters brain, says scientist

23 April, 2004 by Staff Writers

A British scientist has warned that Sanofi-Synthelabo's experimental obesity drug Acomplia could alter the way people think.


Queensland's Xenome files IND for painkiller

22 April, 2004 by Renate Krelle

Xenome -- 25 per cent owned by Medica Holdings (ASX:MCA) -- has filed an investigational new drug (IND) application with the US Food and Drug Administration for its Xen2174 cancer painkiller, which is derived from cone shell venom.


Biotechs, big pharma benefit as first P3 grants awarded

22 April, 2004 by Renate Krelle

The federal government has today ladled out just under 60 per cent of the funding for its five-year $150 million Pharmaceutical Partnerships Program -- known as P3 -- giving 11 pharmaceutical and biotech companies a cash boost to fund drug development.


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd